Abstract:Abstract In recent years there has been much discussion and exploration for a chemopreventive agent for skin cancer. This is something of particular interest for our transplant patients, who are at high risk of developing skin cancers, particularly keratinocyte cancers (KCs). Previous studies have highlighted benefit in immune-competent patients. A recent study by Allen et al. (Allen NC, Martin AJ, Snaider VA et al. Nicotinamide for skin-cancer chemoprevention in transplant recipients. N Engl J Med 2023; 388: 804–12) sought to investigate whether oral nicotinamide supplementation in organ transplant recipients provided any benefit. Their study demonstrated a 24% reduction in invasive SCCs in the nicotinamide group, but overall did not demonstrate a statistically significant reduction in KCs or precursor lesions. Some have challenged that the outcome of this trial will define future chemoprevention practices. We aimed to better define nicotinamide prescribing by surveying all members of the Irish Association of Dermatologists with a 13-item questionnaire focusing on barriers to and thresholds for prescribing oral nicotinamide chemoprevention. We asked respondents how often they prescribe oral nicotinamide for chemoprevention for the following indications: (i) ‘A patient with sun-damaged skin but no focal actinic keratosis’, (ii) ‘Patient with focal actinic keratosis but no history of KC’, (iii) ‘Patient with field actinic change but no history of KC’, (iv) ‘At the time of diagnosis of first KC’ and (v) ‘Patient with more than one KC’. We applied these scenarios for both immunocompetent and immunosuppressed patients. In total, 81% of respondents reported that they prescribe oral nicotinamide for KC chemoprevention. For all chemoprevention indications, we found increased nicotinamide prescribing for immunosuppressed patients. The majority of nicotinamide prescribers introduce treatment in immunocompetent patients at the time of first KC diagnosis (48%) and prescribed oral nicotinamide ‘often’ if the patient had more than one KC (55%). For the same indications in the immunosuppressed cohort, rates of prescribing were 62.5% and 69%, respectively. For secondary chemoprevention, prescribing of nicotinamide (67%) is favoured over acitretin (20%) or a combination of both (11%) in patients at highest KC risk. Overall, 20% of respondents do not prescribe nicotinamide, citing the following reasons as barriers: lack of evidence (50%), cost to patient (22%) and lack of availability (14%). Closer surveillance and changing immunosuppressive protocols reducing skin cancer risk make it difficult to distil the chemopreventive effects of nicotinamide. Our study highlights high current rates of oral nicotinamide prescribing among Irish dermatologists, as secondary chemoprevention particularly in immunosuppressed patients. This baseline will allow for monitoring of potential future changes to skin cancer chemopreventive prescribing patterns among dermatologists. The use of nicotinamide, a drug with a well-established safety profile and favourable price point, warrants further studies before its chemopreventive potential is discounted.

Safety Assessment of Topical Formulation of Nicotinamide Gel (2%), (3%) and (4%) on Skin of Normal Healthy New Zealand White Albino Rabbits.

Nicotinamide as a Skin Whitener: Evidence and Controversies

The role of nicotinamide in acne treatment

In Vitro Human Skin Absorption of Solvent-deposited Solids: Niacinamide and Methyl Nicotinate

Cosmetic benefits of a novel biomimetic lamellar formulation containing niacinamide in healthy females with oily, blemish-prone skin in a randomized proof-of-concept study

Nicotinamide for photoprotection and skin cancer chemoprevention: A review of efficacy and safety

In Vivo Evaluation of Miconazole-Nitrate-Loaded Transethosomal Gel Using a Rat Model Infected with Candida albicans

Topically applied methyl nicotinate evokes a temporary inflammation on human skin

Safety Assessment of High-Purity, Synthetic Nicotinamide Riboside (NR-E) in a 90-Day Repeated Dose Oral Toxicity Study, With a 28-Day Recovery Arm

Nicotinamide (aka Niacinamide) Mitigates SASP-Related Inflammation Induced by Environmental Stressors in Human Epidermal Keratinocytes

Nanomiemgel--a novel drug delivery system for topical application--in vitro and in vivo evaluation

Topical Delivery of Niacinamide to Skin Using Hybrid Nanogels Enhances Photoprotection Effect

Intervention of nicotinamide on human skin melanosome velocity and its distribution change after UVA irradiation

Isotretinoin and α-tocopherol acetate-loaded solid lipid nanoparticle topical gel for the treatment of acne

Study on Influencing Factors of Nicotinamide Transdermal Absorption In Vitro and the Establishment of an Evaluation Method

Toxicology study profile of Nicotinamide mononucleotide after acute and 90-day sub chronic dosing in Wistar rats and mutagenicity tests

A pilot study evaluating the efficacy and safety of retinaldehyde-loaded niosomes against mild-to-moderate acne

Idebenone: a new antioxidant - Part I. Relative assessment of oxidative stress protection capacity compared to commonly known antioxidants

BI14 Nicotinamide prescribing for skin cancer chemoprevention: the Irish experience

Topical Nano Clove/Thyme Gel against Genetically Identified Clinical Skin Isolates: In Vivo Targeting Behavioral Alteration and IGF-1/pFOXO-1/PPAR γ Cues

[The Intervention of Nicotinamide on Skin Melanocyte's Cell Proliferation after UVA (365 Nm) Exposed.].